跳至主要内容
MedPath Trial Home
临床试验
产品
机构
资讯
AI 研究
价格
Search
EN
登录
我们重视您的隐私
我们使用 Cookie 分析网站流量并改善您的体验。请参阅我们的
隐私政策
。
拒绝
接受
ESPEROCT - Health Canada Drug Approval Details
Approvals
/
Health Canada
/
ESPEROCT
Authorized
STANDARD
ESPEROCT
Novo Nordisk Canada Inc
🇨🇦 Health Canada
Approval Date
Jul 4, 2025
Approval ID
59b0327db7db48bb
Company
Novo Nordisk Canada Inc
Type
Standard
Approval Details
Approval Id
59b0327db7db48bb
Drug Approval Canada Name
ESPEROCT
Product Name
ESPEROCT
Status
Marketed
Status Date
2022-03-10
Original Market Date
2022-03-10
Din
02490099
Drug Class
Human
Dosage Form
Powder For Solution
Route Of Administration
Intravenous
Schedule
Schedule D
Ahfs
20:28.16
Atc Original
B02BD02 COAGULATION FACTOR VIII
Atc Name
b 02 bd 02
Aig Number
0161610004
Company Name
Novo Nordisk Canada Inc
Company Address
101-2476 Argentia Road, Mississauga, Ontario, Canada, L5N 6M1
Active Ingredients
ANTIHEMOPHILIC FACTOR VIII (RECOMBINANT, B-DOMAIN TRUNCATED), PEGYLATED
2000 UNIT / VIAL
Authorized
Quick Info
Agency
Health Canada
Country
🇨🇦
Approval Date
Jul 4, 2025
Approval ID
59b0327db7db48bb
Type
Standard
Back to Health Canada Approvals